Effect of duodenal levodopa infusion on blood pressure and sweating

Acta Neurologica Scandinavica
Ville PursiainenEero Pekkonen

Abstract

Non-motor symptoms are a major contributor to quality of life in patients with advanced Parkinson's disease (PD). Duodenal levodopa infusion (DLI) has been shown to alleviate motor fluctuations, but data on its possible effect on non-motor symptoms are scarce. The aim of the study was to assess the effect of DLI on blood pressure (BP), sweating, and non-motor symptoms. We evaluated prospectively and open-label nine male patients with advanced PD (age 68.5 ± 6.2 years) treated with DLI because of daily motor fluctuations. Patients were evaluated using orthostatic test, sweating and skin temperature measurements, Unified Parkinson's Disease Rating Scale (UPDRS), Non-motor Symptom Scale (NMSS), and PDQ-39 before and after 2 months of treatment. Orthostatic BP drop worsened after 1 week of DLI compared with oral medication (24.1 vs 11.9 mmHg, P = 0.011) and remained significant after 2 months of treatment. UPDRS motor scores improved significantly in 2 months compared with baseline (25 vs 19, P < 0.01). Sweating or skin temperatures did not change. Several domains in NMSS (sleep/fatigue, gastrointestinal symptoms, sweating) and PDQ-39 (mobility, bodily discomfort, communication) improved significantly. BP should be monitored during...Continue Reading

References

Nov 1, 1988·Hospital & Community Psychiatry·M R Munetz, S Benjamin
Jan 1, 1988·European Journal of Clinical Pharmacology·D WorthM Lee
Jan 4, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·J M SenardJ L Montastruc
Dec 22, 1999·Pharmacology & Therapeutics·G EmilienS Cragg
Jan 11, 2001·Journal of Neurology·T H HaapaniemiV V Myllylä
Apr 24, 2003·Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)·Jouni NuutinenTapani Lahtinen
Aug 14, 2003·Parkinsonism & Related Disorders·Fabrizio Stocchi
Mar 16, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Ville PursiainenVilho V Myllylä
Mar 21, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·Janne LudwigRalf Baron
Aug 4, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Kallol Ray ChaudhuriAnthony H V Schapira
Apr 3, 2008·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
May 9, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Holger HonigK Ray Chaudhuri
Nov 12, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Claire L TomlinsonCarl E Clarke
Jan 26, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Pablo Martinez-MartinUNKNOWN NMSS Validation Group

❮ Previous
Next ❯

Citations

Mar 4, 2014·Internal Medicine·Jun SuzukiTakumi Kurosu
Dec 18, 2013·Expert Review of Neurotherapeutics·Adolfo Ramirez-Zamora, Eric Molho
Apr 15, 2016·Neurodegenerative Disease Management·Diego Santos GarcíaNatividad Mariscal Pérez
Jul 31, 2013·Journal of the Neurological Sciences·Diego Santos-García, Raúl de la Fuente-Fernández
Jul 22, 2016·Neurodegenerative Disease Management·Francesc ValldeoriolaJuan Carlos Parra
Jun 24, 2017·CNS Drugs·Eva Schaeffer, Daniela Berg
Sep 8, 2016·Movement Disorders Clinical Practice·Matej Skorvanek, Kailash P Bhatia
Oct 21, 2015·Journal of the American Geriatrics Society·Fuyuki TatenoTsuyoshi Ogata
Nov 29, 2020·Parkinsonism & Related Disorders·Nicki NiemannJoseph Jankovic

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.